Free tool
FAERS Monitor: Hicon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021305 or its brand name (Hicon, Sodium Iodide I-131). Reports on generic versions are filed under their own applications.
Reports
960
Serious
900
94% of reports
Hospitalization
63
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypothyroidism385
- endocrine ophthalmopathy36
- treatment failure26
- acute myeloid leukaemia24
- dacryostenosis acquired24
- hyperthyroidism23
- parathyroid tumour benign21
- abortion spontaneous20
- hyperparathyroidism19
- lacrimation increased19
- nausea19
- breast cancer17
- maternal exposure during pregnancy17
- thyroid cancer17
- sialoadenitis16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 33 |
| 2008 | 77 |
| 2009 | 56 |
| 2010 | 56 |
| 2011 | 263 |
| 2012 | 173 |
| 2013 | 82 |
| 2014 | 14 |
| 2015 | 17 |
| 2016 | 20 |
| 2017 | 6 |
| 2018 | 29 |
| 2019 | 49 |
| 2020 | 14 |
| 2021 | 50 |
| 2022 | 8 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,199 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endocrine ophthalmopathySignal | 36 | 948.9 | 683.8 | 31,774 |
| parathyroid tumour benignSignal | 21 | 638.7 | 415.8 | 12,381 |
| dacryostenosis acquiredSignal | 24 | 415.1 | 278.6 | 9,328 |
| hypothyroidismSignal | 385 | 267.4 | 247.3 | 100,834 |
| sialoadenitisSignal | 16 | 260.3 | 159.7 | 3,832 |
| hyperparathyroidismSignal | 19 | 203.9 | 130.3 | 3,602 |
| hyperthyroidismSignal | 23 | 34.9 | 23.3 | 722 |
| acute myeloid leukaemiaSignal | 24 | 33.8 | 22.8 | 731 |
| thyroid cancerSignal | 17 | 31.0 | 19.3 | 463 |
| lacrimation increasedSignal | 19 | 13.8 | 8.8 | 213 |
| abortion spontaneousSignal | 20 | 10.9 | 7.1 | 171 |
| treatment failureSignal | 26 | 6.9 | 4.7 | 125 |
| maternal exposure during pregnancySignal | 17 | 4.2 | 2.6 | 38 |
| breast cancerSignal | 17 | 4.0 | 2.5 | 35 |
| nausea | 19 | 0.5 | 0.3 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.